Member Info for Merchantbanker

Come on guys, you can't honestly be excited that 9 months down the line they have seconded a mid level Omega scientist to the development of the project? With all due respect to the guy, who knew that the missing ingredient over the last 9 months was this guy?! It would be a different ball game if it indicated TT to production, but the fact that Omega have been drafted into the development does not speak volumes for the imminent success of this test and I would find it very difficult to accept a case to the contrary. However this is circumstantial from liens from a linkedin profile, so not something i will take as Bible.

Sorry I read this differently. Why are Omega involved in the development of a test? I thought development was already taken care of and they only wanted manufacturing capacity? For me it’s not a good sign for avacta if they have had to get more hands involved in development.

Lol- I think I’ll be fine.

Why are Omega involved in a development project of a test on behalf of avacta? I thought that was Cytiva and BBI job? If Omega have been brought into the development surely that’s not a good sign that they have succeeded? Sounds like another roll of the dice to me getting more people involved in trying to develop a test.

I hope for you that it is a good sign and Avacta test is progressing. I though Avacta just wanted Omegas manufacturing capacity? Happy for AS to spend his placing money on Omega staff trying to put a square peg in a round hole in making Acacta test work! GLA

"wrong type testing"

Mologic have been working on the Antigen test since March. There are more complexities in achieving the antigen test than the antibody test. Largely relating to sampling. A blood sample is a blood sample, it is visible, distinguishable and easier to confirm a sample has successful been achieved. A swab is much more complex and can't see the sample and the presence of antigens and access to sampling of the swab is more difficult. There are also further complexities with reagents for the antigen test than the antibody test.

So it's not the wrong type of test first, its just a case they antibody test was achieved quicker.

"Not pushing enough for the right test"

I give them 10/10 in this regard that partnering with UK RTC and Oxford vaccine and Mologic has given them exactly the right tests and the best possible portfolio they could have

"enjoying holiday when the time for action"

Come on, really?!

"No updates\news to stop MM"

No updates is not quite fair, but yes lots we are not being told, the reason it is undervalued.

Key word.....

“Trialed”

These companies will make a lot of noise over very little. The fact Mologic trialed Aptamers may be significant for Aptamer and something to make a load of noise about nothing. But Mologic trialed lots of different reagents. They are funding Oxford work on antibody development.

https://www.ndcn.ox.ac.uk/news/developing-diagnostics-for-covid-19

Okehurst - I am certain that the mologic test will use traditional antibodies, i am sure i have read somewhere but can't think where. It's quite clear the reagent isn't really so much the problem, it's the sampling. I very much doubt a man made reagent will make it to a commercial test.

The thing is, test developers have their pick of reagents. It is much more likely to lead to success than having one source of reagents and trying to make as test to work it. To use an analogy, it's like if i make engines for F1 cars, some F1 teams make their own engines some make the rest of the car but source the engine. If i am a new engine maker if my engine is any good, other teams will buy it. If i have to try and make my own car to use my engines, i'm likely to fail as i don't have experience making F1 cars, and the fact nobody else is interested in it suggests it isn't as good as i think it is. Also the engine is just one major part of many, and there are so many other parts to get right, and if i do i can only use my engine so if it is no good i'm screwed.

Okehurst - what are you on about mate.... you can't seriously still be thinking Omega are waiting on Avacta's test?!

The Mologic test is not a nasopharyngeal swab. An anterior nasal swab is a respiratory swab. It will most likely be a swab for the accessible part of throat and anterior nasal.

Note the wording in the tender...

"Please note that product offerings which can only use a nasopharyngeal specimen shall not be permitted under this tender."

It is possible that a LFT could work with different sample types depending on the use. The technology in the strip is the same, reagents the same, it's just about the collection of the sample and the likelihood of it containing the required level of target nucleocapsid protein. For example, UK Gov could say they want a nasal swab, maybe another buyer wants to use the test with a nasopharyngeal swab. They are not producing a test for one specific customer to that customer's needs, they are trying to produce the best test possible, at low cost to roll out globally.

Spotted this little gem in an article published "A Day in the life" of the lead R&D for diagnostics development at LTSM.

"Working in translational research I often have a meeting with our industrial partners to discuss results, most fruitfully with our Mologic consortium, results are exciting and progress is rapid."

"We are the FIND evaluation site in the UK, so our work is part of an international multi-site collaboration, and results go to WHO and aid procurement of the best tests with independent and transparent data."

https://www.lstmed.ac.uk/a-day-in-the-life-of-emily-adams

The business case for ODX is just going from strength to strength by the day at the moment. All the patience and groundwork put in by the company is about to translate into. Serious cash inflow in high volume sales of the most in demand lateral flow tests.
Antigen test and abc-19 are both billion $ products and omega will sell as many as they can make

Omega need to CE mark themselves to sell under their own brand which is more profitable than being a contract manufacturer for Mologic. Unlike the ABC-19. The process of TT and validation is still the same, so really not much changes other than it needs an independent CE mark.

Well, what to say.... there are times this year when you would never have believed there would be positive sentiment with a confirmed antigen test and so much progress on antibody and vaccine tie up and still be sub £1. The value gap for investors to be closed during Q1 is substantial and today was a real turning of the tide.

All the naysayers writing Omega off have massive egg on their face today. OK TT is not yet complete and we are not ready for sales tomorrow, but we are very close now, and the 500k capacity is well timed with where we are at. If you look at Omega messaging they have been spot on, you can see how the capacity increase is totally in line with todays status update. I suspect the vaccine is with us earlier than expected so the plans for capacity may need to be fast tracked to deliver both tests.

This is incredible news today. Every company out there wants a validated antigen test, and we now have one, along with the worlds best IgG antibody test.

There are some real lessons to be learnt here as an investor. Omega have done things with integrity, they have learnt as they went along, they have created a highly profitable business plan, not over ramped it but just got on with business and made sure they are well placed in the market when LTF is opened up from the regulators. This is how a AIM company should operate. This is how a CEO should operate. There will be a lot of investors looking back in a few months time asking why they overlooked or wrote off ODX, because they failed to see exactly what was there infront of them the whole time and based their opinion purely on share price. So much money is lost on failed dreams and empty promises. In Omega they have their strategy spot on. The recognise the value is in making and selling quality tests. Instead of trying to sell us a dream and say they can produce their own and it will be the best and will sell gazilions, they got into bed with the best from day one, and said we want the best possible tests and we want to offer what we are strong at, making, selling, distributing.

We have been though some tough months, with the city making sure they got the best deal from a placing as they always do. We have had IIs selling over 35% of the company. This has created opportunity. IMO when these opportunities present you have to take advantage as they are few and far between. When sentiment was low and the sp down, the wise ones were buying whilst the inexperienced were moaning and following the overhyped stocks.

We have some way to go yet, but i am in no doubt that the next 3/4 months will be success after success. And in the process kicking this virus out the park.

I suspect we will have another good few days next week, leading us well placed come Jan. 2021 the year of the lateral flow, and Omega have 3 of the best.

I suspect we have maximum a couple of weeks of frustration left, and in my opinion it will be worth it. 500k-2m a week in the next few months.
Product validations will obviously greatly help us.

Because they will run out too quickly because they don't have the manufacturing scaled up yet. You used the overseas supply whilst you can get it until your supply chains are up to speed. Same model as PPE.

This is the kind of development that we would normally be saying "i hope we don't get a speeding ticket"

1 test should open the door for others....
Convenient they have now moved to sign off home test in 3 days before the MHRA approval of the ABC-19 test is required.
All about 2021 year of the LFT and omega will clean up.

have you not worked out news will not be timed around benefiting Omega!!! It will be timed around when the powers that be want details made public.

You can by 10k but not 1k with IG.

There is only one test we know of where the government have agreed to finance the components, which is the UK RTC with the £10m Abingdon agreement. Any other tender they are buying complete test kits.

Well considering it says in the article itself in the Guardians own words that the Government will not refuse to order any more.......

"The government has refused to give an undertaking not to award any further public contracts to Abingdon Health pending the outcome of the case and will not explain its reasons, say the lawyers."

From what they know about the new strain, the Antigen test should be fine. Antigen test usually will detect the Nucleocapsid protein. From what we are told about the new strain this is unchanged.
Regarding the antibody test, comment from Oxford/AstaZenica will help but it is unlikely that minor mutations will significantly differ in genetic code that antibody response becomes ineffective. The antibody tests may become even more important